Gilead Sciences Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies; U.S. NDA Submission Planned For Q2
Hal Lindon